All News

RheumNow Podcast square

Repurposing & Pipeline (8.8.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.

Read Article
Jo1.gottrons.jpg

Dermatomyositis Reviewed

Jack Cush, MD

Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.

Read Article
labs.tubes_.jpg

Inefficiencies of ANA Testing

Jack Cush, MD

The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs).

Read Article
JIA.oligoarticular.jpg

Juvenile Idiopathic Arthritis - NEJM Review

Jack Cush, MD

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).

Read Article
RheumNow Podcast square

A New RA Approval (8.1.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Rituximab is not Superior in EGPA

Jack Cush, MD

A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.

Read Article
glomerulonephritis.jpg

HCQ Preserves Renal Function in Lupus Nephritis

MedPage Today

Lupus nephritis patients on long-term therapy with hydroxychloroquine showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated.

Read Article
RheumNow Podcast square

CKD & Osteoporosis Rx Revisited (7.25.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors

Jack Cush, MD

Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.

Read Article
antibody (Keep)

Clinical Associations with Anti-RNA Polymerase III Antibodies

Jack Cush, MD

A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome outcomes.

Read Article
RheumNow Podcast square

NHANES, Numbers, & Risk (7.18.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".

Read Article
Retrospective study of FDG-PET scans at Int. Medicine tertiary hosp (2015-2020), included 260 adult IM pts - indications: infx 42%, inflammation 35%, suspected CA 17%. 80% were helpful; 40% Rx changed. 23% neg. results; 9% made the Dx; 43% PET superior to other imaging. Less https://t.co/2UG2npJgRg
Dr. John Cush RheumNow ( View Tweet)
RA & GOUT? S. Korean study of 34,356 new RA pts vs 103,068 controls. RA had 2.7 X higher risk of gout vs non-RA. Seropos & Seroneg equal incr risk (aHR 2.8 & 2.6), slightly higher in SPRA(aHR 1.07). RA on b/tsDMARDs had lower risk (aHR, 1.93) vs Untreated (aHR, 2.78). https://t.co/P0oqq5bVnq
Dr. John Cush RheumNow ( View Tweet)
PsA is worse in women--why? 100 PsA pts, serum study of differentially expressed proteins - 20 times more sex-specific DEPs in PsA males than females (PsA vs controls). In women leukotriene A-4; and in men IL-36, NEK7 & PIK3CA/PIK3R1 were significant predictors. https://t.co/JzI1n6Hf5G
Dr. John Cush RheumNow ( View Tweet)
New ICD-10 Diagnostic Code -- R76.81 -- for ’At-Risk RA’ (AKA Clinically suspect arthralgia or Pre-clinical RA); this applies to pts w/ abnormal RF or ACPA without having RA. Thanks to Dr. Kevin D. Deane for leading this effort. https://t.co/14I6RCZrXb https://t.co/YxTwPB0YDQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 457 Autoimmune liver disease pts found 42.5% with Polyautoimmunity. Predictors included ANA positivity (78 vs 47%), ANA titers, dsDNA (12 vs 2%), RF+ (25 vs 9%), disease duration, low albumin, high ESRs. https://t.co/Socl6XWU9a https://t.co/8qomVBh3KP

Links:

Dr. John Cush RheumNow ( View Tweet)
La Paz study of 903 RA pts; 136 (14.5%) were D2T-RA, 96 for inefficacy. They define early vs Late D2T-RA=44.5 mos, & differed>> Early D2T-RA (1/3) pts more likely to have anxiety or depression (76% v 0), higher CRP @6mos, & time to develop D2TRA (35 vs 70 mos) https://t.co/KFG68y9Uq5
Dr. John Cush RheumNow ( View Tweet)
🧬 Myositis-Specific Autoantibodies (MSAs) – 2025 Update MSAs aren’t just diagnostic—they predict phenotype, prognosis, & treatment response. 👇 Infographic #RheumTwitter #Myositis #MedEd @IhabFathiSulima @DrAkhilX https://t.co/91U5s88AdB

Links:

Aravind Palraj Rheumat_Aravind ( View Tweet)
SSB, > SSA, Abs are signif associated w/ abnormal DLCO (AUC 0.791) in Sjogrens syndrome, esp in assoc. w/ LIP- lymphocytic interstitial pneumonitis. These findings more likely in quadruple positive Sjogrens w/ RF/ANA/SSA/SSB positivity. https://t.co/s6IyRzfXiN https://t.co/rKDBovTOpl

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/hp7sFR6kLa
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×